Background:
Antibody drug conjugates (ADC’s), bispecific engagers and adoptive cell therapy are novel therapeutic approaches that rely on targeting tumor specific and tumor associated antigens in solid tumors. These are underutilized treatment modalities in thoracic oncology.
• Prior studies have identified differential expression of surface expressed proteins (‘the surfaceome’) and cancer testis antigens in SCLC translational subtypes. We sought to expand this approach to include molecular subtypes of NSCLC.